Century Therapeutics, Inc. (IPSC) Stock Score, Valuation & Financial Research
Century Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 31/100.
Quick answer for IPSC
Century Therapeutics, Inc. currently has a Wall Street Score of 31/100. The stored market price is $1.94. Its financial score is 28/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Century Therapeutics, Inc. does
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another
IPSC financial snapshot
- Wall Street Score:
- 31/100
- Current price:
- $1.94
- Market capitalization:
- $167.9M
- Revenue:
- $0
- Net income:
- $-109.8M
- Free cash flow:
- $-104.7M
- Cash:
- $49.6M
- Total debt:
- $34.6M
- EPS:
- -0.11
- Financial score:
- 28/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is -1.0%.
- Free cash flow is $-104.7M, showing cash burn in the current stored period.
- The balance sheet shows $49.6M of cash versus $34.6M of total debt, leaving more cash than debt.
- The current research record carries a missing revenue history warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 28/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research IPSC
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.